These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37959834)

  • 1. Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors.
    Hou X; Wang Y; Yang Y; Xiao Z
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Tan PK; Liu S; Gunic E; Miner JN
    Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
    Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
    Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout.
    Wu JW; Yin L; Liu YQ; Zhang H; Xie YF; Wang RL; Zhao GL
    Bioorg Med Chem Lett; 2019 Feb; 29(3):383-388. PubMed ID: 30579795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
    Hou Z; Ma A; Mao J; Song D; Zhao X
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications.
    Song D; Zhao X; Wang F; Wang G
    Eur J Pharmacol; 2021 Sep; 907():174291. PubMed ID: 34216576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.
    Cai W; Wu J; Liu W; Xie Y; Liu Y; Zhang S; Xu W; Tang L; Wang J; Zhao G
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29382075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of 3-phenyl substituted pyridine derivatives as potential dual inhibitors of XOR and URAT1.
    Yang C; Cai H; Zhu X; Zhang L; Li J
    Eur J Med Chem; 2024 May; 271():116407. PubMed ID: 38663283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
    Zhao Z; Liu J; Yuan L; Yang Z; Kuang P; Liao H; Luo J; Feng H; Zheng F; Chen Y; Wu T; Guo J; Cao Y; Yang Y; Lin C; Zhang Q; Chen J; Pang J
    Eur J Med Chem; 2022 Nov; 242():114682. PubMed ID: 36001935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.
    Zheng F; Mai S; Cen X; Zhao P; Ye W; Ke J; Lin S; Hu H; Guo Z; Zhang S; Liao H; Wu T; Tian Y; Zhang Q; Pang J; Zhao Z
    Bioorg Chem; 2024 Jun; 147():107381. PubMed ID: 38669781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
    Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
    Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
    Shi X; Zhao T; da Silva-Júnior EF; Zhang J; Xu S; Gao S; Liu X; Zhan P
    Expert Opin Ther Pat; 2022 Dec; 32(12):1175-1184. PubMed ID: 36625031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.
    Zhao ZA; Jiang Y; Chen YY; Wu T; Lan QS; Li YM; Li L; Yang Y; Lin CT; Cao Y; Zhou PZ; Guo JY; Tian YX; Pang JX
    Acta Pharmacol Sin; 2022 Jan; 43(1):121-132. PubMed ID: 33767379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
    Dong Y; Zhao T; Ai W; Zalloum WA; Kang D; Wu T; Liu X; Zhan P
    Expert Opin Ther Pat; 2019 Nov; 29(11):871-879. PubMed ID: 31593642
    [No Abstract]   [Full Text] [Related]  

  • 16. Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.
    Huang W; Jiao S; Chen S; Chen Y; Yang Z; Wang W; Cao Z; Li Z; Zhang L
    Bioorg Med Chem; 2022 Dec; 75():117073. PubMed ID: 36347120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
    Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
    Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents.
    Ao GZ; Zhou MZ; Li YY; Li SN; Wang HN; Wan QW; Li HQ; Hu QH
    Bioorg Med Chem; 2017 Jan; 25(1):166-174. PubMed ID: 28340987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.
    Li S; Liao H; Luo L; Meng B; Zheng F; Sheng L; Zhao H; Huan Y; Lei L; Zhai J; Zhao K; Tian J; Wu T; Li G; Pang J; Huang H
    Eur J Med Chem; 2024 Apr; 269():116327. PubMed ID: 38547733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-Absorber.
    Saito H; Toyoda Y; Takada T; Hirata H; Ota-Kontani A; Miyata H; Kobayashi N; Tsuchiya Y; Suzuki H
    Nutrients; 2020 May; 12(6):. PubMed ID: 32486008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.